長森藥業成立于2012年，是由全球知名化學藥物研發專家領銜的創新藥研發公司。公司凝聚了一批在新藥研發頗有成就的研發帶頭人和年輕有為的藥物化學科學家，本著“創新、卓越”的宗旨，致力于自主研發國際領先的，擁有全球知識產權的創新藥產品，滿足臨床未竟需求。公司聚焦抗病毒、腫瘤免疫、自身免疫疾病等領域的原研藥開發與產業化，以免疫學機理和臨床轉化為基礎，構建并發揮自主研發體系優勢，憑借豐富的臨床洞察與成果轉化能力，開展滿足概念驗證（Proof of Concept）熱門靶點的創新藥開發。

自成立以來，長森藥業已開展多個自主研發的小分子創新藥項目（FIC，first in class），多個產品進入臨床試驗階段，其中兩項臨床研究已進入臨床2期研究階段。核心產品臨床評估指標達到國際領先水平，有希望成為相關領域的重大突破（BIC，best in class）。預計未來三到五年，更多自主研發項目進入后期臨床研究的同時，公司也將邁入產業化和商業化的高速發展階段。 

公司總部位于閔行莘莊工業園，建有近4000m2的創新藥研發實驗室及轉化中心。公司是國家高新技術企業，上海市“專精特新”中小企業，擁有授權發明專利40余項。

Founded in 2012, Longwood Biopharma is an innovative drug discovery company led by world-renowned experts in chemical drug discovery and development. With a team of accomplished R&D experts and young talented medicinal chemistry professionals, the company is dedicated to the independent research and development of world-class innovative drug products with global intellectual property rights to fulfill the unmet clinical needs. The company focuses on the development and industrialization of innovative drugs in the fields of anti-virus, tumor immunity and autoimmune diseases, leveraging the advantages of our well-built R&D system. Based on our rich clinical insights and results translation capabilities, we are developing innovative drugs for the hot targets with proof-of-concept.

Since its establishment, Longwood Biopharma has carried out several self-developed small molecule innovative drug projects (FIC, first in class), which several products in clinical trials, two of them in clinical study phase 2. With world-class performance in clinical evaluation, our core product are expected to become major breakthroughs in related fields (BIC, best in class). It is expected that in the next three to five years, more self-developed projects will enter late-stage clinical studies while the company will move into a high-speed development stage of industrialization and commercialization. 

Headquartered in Xinzhuang Industrial Park, Minhang District, Shanghai, the company has an innovative drug R&D center of nearly 4,000m2. The company has qualified as National High-Tech Enterprise, Shanghai Specialized&Sophisticated SME, and has over 40 authorized invention patents.